Tamtam Try Tamtam free
Quest Diagnostics logo

Quest Diagnostics account plan

Extensive clinical diagnostic testing

At a glance

Quest Diagnostics is a US clinical laboratory company with 2025 net revenues of $11,035 million and nearly 57,000 employees.

Quest Diagnostics provides diagnostic testing in the United States, serving about one-third of US adults and about half of US physicians and hospitals each year through ~2,400 patient service centers; it also operates LifeLabs in Canada. 2025 net revenues were $11,035 million (+11.8%; organic growth 5.3%), with operating income of $1,556 million and net income attributable to Quest of $992 million. It processed ~244 million test requisitions in 2025 and has nearly 57,000 employees. Its customers are physicians, hospitals, payers, life insurers and consumers.

Business units

Strategic priorities

Growth across physician, hospital and consumer channels
High single-digit growth in physicians, double-digit growth in hospitals in Q3 2026, and consumer health growth expected to exceed 30% for the year.
Collaborative Lab Solutions with health systems
Co-Lab Solutions across all 21 Corewell Health hospitals; Co-Lab Solutions is expected to generate about $1 billion of revenue in 2026.
Outreach and lab acquisitions
M&A targets 1-2% revenue growth a year, including an agreement to acquire outreach lab assets from a Northeastern US health system.
Consumer channel
QuestHealth.com is a $100 million run-rate business; an Apple Health app panel of over 50 biomarkers launches around year-end, with partners including WHOOP, Oura and Function Health.
Cost savings through Invigorate, automation and AI
Invigorate targets 3% annual cost savings; automated aliquoting runs in 10 labs and AI collaboration is under way with Google Cloud.

Latest results

In Q3 2026 net revenues were $3,097 million (+10.0%), with DIS organic growth of 10.1% and volume up 14.5%, of which 9.5% came from the Corewell Health relationship and Fresenius dialysis testing. Revenue per requisition fell 4.2% because of that routine-testing mix. Reported diluted EPS was $2.78 and adjusted diluted EPS $3.00 (+15.4%). Full-year 2026 guidance was raised to revenues of $12.065-12.105 billion and adjusted EPS of $11.25-11.35, with capex of about $550 million.

Investments and deals

Corewell Health joint venture
51/49 lab JV in Michigan closed in January 2026; a new Michigan lab is due to be operational during 2027.
Project Nova
Epic-based modernization of Order to Cash running to 2031-2032; it moved to build phase with the first Epic lab deployment in fall 2027.
Lab asset acquisitions
Spectra Laboratories assets bought from Fresenius for $84 million; LifeLabs acquired in 2024.
Capex and shareholder returns
Capex was $527 million in 2025 and is guided at about $550 million for 2026; an additional $1 billion buyback was authorized and the dividend raised 7.5% to $0.86 per quarter.

Challenges and risks

PAMA Medicare fee cuts
The 2027 impact is estimated at about 1% of total revenues; Quest lobbies for the RESULTS Act.
Payer and policy pressure
Payer utilization controls, OBBBA and expiry of ACA tax credits could cost up to 50-60 bp of revenue by 2028.
Cybersecurity
A cybersecurity incident on a test-ordering system was disclosed on October 22, 2026.
Pricing mix and competition
Unit price is generally flat, and Quest competes with hospital labs and Laboratory Corporation of America; labor supply is a stated risk.

What leadership says

“We delivered revenue growth of 10% and adjusted EPS growth of over 15% on continued strength across our physician, hospital and consumer channels, complemented by productivity gains from automation and AI.”

Jim Davis, Chairman, CEO and President · Q3 2026 results press release, 2026-10-22

“We expect co-lab solutions to generate approximately $1 billion in annual revenues in 2026.”

Jim Davis, Chairman, CEO and President · Q4 2025 earnings call, 2026-02-10

“further advanced our position as the premier lab engine powering the wellness industry”

Jim Davis, Chairman, CEO and President · Q4 2025 earnings call, 2026-02-10

Where a supplier can help

Lab automation and AI
The Invigorate 3% savings target and automation and AI in labs open doors for lab robotics, AI imaging and workflow vendors.
Epic migration support
Project Nova's Epic-based Order to Cash modernization needs implementation, data migration and testing partners through 2031-2032.
Security of ordering systems
The cybersecurity incident on a test-ordering system makes security assessment and monitoring services relevant.
Consumer and digital health partnerships
The consumer channel and the Apple Health app panel call for digital marketing, ecommerce and wearables integration partners.
Health system lab outsourcing
Co-Lab Solutions and the new Michigan lab create needs for lab construction, equipment and logistics suppliers.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Quest Diagnostics?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Quest Diagnostics

What does Quest Diagnostics do?

Quest Diagnostics runs clinical laboratory testing for physicians, hospitals, payers and consumers in the United States, plus risk assessment for life insurers and healthcare IT.

What is Quest Diagnostics' revenue?

2025 net revenues were $11,035 million (+11.8%). 2026 guidance is $12.065-12.105 billion.

How many employees does Quest Diagnostics have?

Nearly 57,000, including ~6,800 at LifeLabs in Canada.

Who leads Quest Diagnostics?

Jim Davis is Chairman, CEO and President, and Sam Samad is CFO.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)